---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-017568"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2024-02-21T23:59:59+00:00"
generated_at: "2026-06-05T22:09:30.416286+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CRISPR Therapeutics 2023: CASGEVY approved in 5 countries; Q4 net income $89.3M

## Summary
- CASGEVY (exa-cel) approved in U.S., EU, Great Britain, Bahrain, KSA for SCD and TDT; ~35,000 patients in U.S. and Europe.
- Q4 net income $89.3M vs net loss $110.6M in Q4 2022; cash $1.7B at year-end, pro-forma >$2.1B after $200M milestone and $280M offering.
- Clinical trials ongoing for next-gen CAR T (CTX112, CTX131) and in vivo programs (CTX310, CTX320); CTX112 trial in SLE planned H1 2024.
- R&D expenses $95.1M in Q4 (down from $103.6M), G&A $16.5M (down from $21.2M); collaboration expense net $20M.
- Vertex paid $170M in 2023 milestones; eligible for additional $160M milestones plus royalties.

## SEC filing metadata
- accession: 0000950170-24-017568
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2024-02-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017024017568/0000950170-24-017568-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017024017568/crsp-20240221.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-017568
- JSON: https://secwatch.observer/filing/0000950170-24-017568.json
- Plain text: https://secwatch.observer/filing/0000950170-24-017568.txt

## Key facts
- Earnings Releases
  CRISPR Therapeutics AG reported financial results for the year ended December 31, 2023.
  - Period: the year ended December 31, 2023
  - Result: reported results
  source text: On February 21, 2024, CRISPR Therapeutics AG announced its financial results for the year ended December 31, 2023 and other business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674416/000095017024017568/0000950170-24-017568-index.htm
- Earnings Releases
  CRISPR Therapeutics AG reported financial results for the fourth quarter ended December 31, 2023.
  - Period: the fourth quarter ended December 31, 2023
  - Result: reported results
  source text: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674416/000095017024017568/0000950170-24-017568-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.